利培酮口服液治疗精神分裂症急性兴奋状态对照研究

目的探讨利培酮口服液治疗精神分裂症急性兴奋状态患者的临床疗效和安全性。方法将56例精神分裂症急性兴奋状态患者随机分为两组各28例，研究组口服利培酮口服液治疗，对照组肌肉注射氟哌啶醇，观察7d。于治疗前及治疗第3d、7d末采用阳性与阴性症状量表-兴奋条目评定临床疗效，副反应量表评定不良反应。结果治疗7d末，研究组兴奋症状好转率为75．0％，对照组为78．0％，两组好转率无显著性差异（χ2=0．100，P〉0．05）。两组治疗第3d、7d末阳性与阴性症状量-表兴奋条目评分均较治疗前有显著下降（P〈0.01）；同期两组间比较均无显著性差异（P〉0．05）。研究组不良反应发生率为32．1％，但程度均较轻微；对照组发生率为75％，且程度较重；两组均以锥体外系反应为主。结论利培酮口服液治疗精神分裂症急性兴奋状态疗与氟哌啶醇效果相当，但不良反应发生率低于氟哌啶醇。

A control study of risperidone oral solution in acute excitement of achizophrenia

Objective To explore the efficacy and safety of risperidone oral solution in acute excitement of achizophrenia. Methods Fifty-six schizophrenics with acute excitement were randomly divided into two groups of 28 patients each,research group took risperidone oral solution and control group were intramuscularly injected with haloperidol for 7 days. Effieacies were assessed with the Positive and Negative Syndrome Scale Excited Component （PANSS-EC） before treatment and at the ends of the 3rd and 7th day treatment, adverse reactions with the Treatment Emergent Symptom Scale（TESS）. Results At the end of the 7th day,improvement rates of excited symptom were respectively 75.0% in the research and 78.0% in the control group,which showed no significant differenee（χ2= 0. 100, P〉0.05）. Scores of excited component of both groups lowered more significantly at the ends of the 3rd and 7th day compared with pre-treatment（P〈0.05） ;there was no significant difference in synchronization group comparison（P〉0.05）. Incidence of adverse reactions was 32.1% and its level milder in the research and 75% and heavier in the control; adverse reactions of both groups were mainly extrapyramidal reactions. Conclusion Iisperidone oral solution has an equivalent effect to haloperidol intramascular injection on acute excitement of schizophrenia but incidence of adverse reactions of the former is lower.